Quantitative analysis of insulin-like growth factor 2 receptor and insulin-like growth factor binding proteins to

Dan Tian1, Isaiah Mitchell2, Pamela K Kreeger3,4

  • 1Department of Biomedical Engineering, 4553 WI Institute Medical Research, University of Wisconsin-Madison, 1111 Highland Ave, Madison, WI, 53705, USA. dtian@wisc.edu.

BMC Systems Biology
|February 11, 2016
PubMed
Abstract

Insights

Insulin-like growth factor-binding proteins (IGFBPs) are the main regulators of the insulin-like growth factor 1 receptor (IGF1R) network, not IGF2R. High IGFBP levels dominate IGF1R activity, impacting cancer development.

Area of Science:

  • Oncology
  • Systems Biology
  • Molecular Endocrinology

Background:

  • The insulin-like growth factor (IGF) system regulates cell proliferation, differentiation, and apoptosis, making it a key target in cancer therapy.
  • The IGF system comprises ligands (IGF1, IGF2), receptors (IGF1R, IGF2R), and IGF-binding proteins (IGFBPs) that modulate ligand availability.
  • While individual IGF system components are understood, their integrated network behavior in regulating cell functions remains unclear.

Purpose of the Study:

  • To elucidate the relative importance of different regulatory mechanisms within the IGF network.
  • To determine the dominant factor controlling IGF1R phosphorylation and subsequent network activation.

Main Methods:

  • Developed a mass-action kinetic model of the IGF network, including cell surface binding, phosphorylation, and intracellular trafficking.
  • Calibrated and validated the model using experimental data from the OVCAR5 ovarian cancer cell line.
  • Analyzed the model to assess the impact of IGF2R and IGFBP levels on IGF1R phosphorylation, referencing The Cancer Genome Atlas (TCGA) data.

Main Results:

  • IGF2R would need to be 320-fold greater than IGF1R to reduce phosphorylated IGF1R (pIGF1R) by 25%, a level unlikely in ovarian, breast, and colon cancers.
  • IGFBPs would need to be 390-fold greater than IGF1R to achieve similar inhibition, a level attainable in cancer.
  • pIGF1R levels were insensitive to changes in parameters governing the IGF2R pathway, indicating a minor regulatory role for IGF2R.

Conclusions:

  • IGF2R plays a minimal role in regulating IGF1R activity across various conditions.
  • IGFBPs, due to their typically high expression levels, represent the dominant mechanism controlling IGF network activation and IGF1R activity.
  • Understanding IGFBP regulation is crucial for targeting the IGF network in cancer therapy.

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.8K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
19.2K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.6K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.9K